AUTHORS
Raphael Steiner, MD, Conner Liddle2, Olivia Tran3, Sairah Ahmed, MD4, Paul J. Hampel, MD5, Sameer A. Parikh, MBBS6, Esther Drill, DrPH7, Harsh Rohit Shah, DO8
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 University of Utah Health, Salt Lake City, Utah, United States
3 MD Anderson Cancer Center, Houston, Texas, United States
4 MD Anderson Cancer Center, Houston, Texas, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 University of Utah Health, Salt Lake City, Utah, United States
ABSTRACT
Introduction:
Classic Hodgkin lymphoma-type Richter transformation (CHL-RT) is a rare complication of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). With limited prospective data to guide management of CHL-RT, management defaults to standard of care approaches in de novo classic Hodgkin lymphoma. In the S1826 trial, the addition of nivolumab to doxorubicin, vinblastine, and dacarbazine (N+AVD) improved progression-free survival (PFS) in patients with advanced-stage de novo classic Hodgkin lymphoma. However, N+AVD activity in CHL-RT has not been reported, and the T-cell exhaustion associated with CLL/SLL precludes direct assumption of similar efficacy in a CHL-RT population. We conducted a multicenter retrospective study to evaluate the efficacy and safety of first-line N+AVD in patients with CHL-RT.
Methods:
We retrospectively identified patients with biopsy-proven CHL-RT treated with first-line N+AVD across four academic centers. Baseline clinicopathologic characteristics, treatment exposure, and adverse events were collected. PET/CT response assessment was performed at each center using the Lugano 2014 criteria. Progression-free survival (PFS) and overall survival (OS) were measured from CHL-RT diagnosis and estimated using the Kaplan-Meier method.
Results:
Nineteen patients with CHL-RT treated with first-line N+AVD were included. Median age at CHL-RT diagnosis was 70 years (range, 56-82 years); CLL/SLL was diagnosed at a median time of 3 years (range 0-18 years) before the CHL-RT diagnosis. Most patients were male (58%), and all had advanced-stage disease (stage III, 26%; stage IV, 74%). The median International Prognostic Score (IPS) was 2 (range 0-5), and 47% presented B symptoms. Patients had received a median of 1 (range 0-4) prior line of therapy (42% active observation, 32% BTK inhibitor, 21% venetoclax, 1% chemotherapy) for CLL/SLL at the time of CHL-RT diagnosis.
Overall, 83% of patients received the intended 6 cycles of N+AVD; no patient received consolidative radiotherapy. Only one patient continued CLL/SLL therapy (acalabrutinib) during N-AVD. No patient had progressive CLL/SLL and required new CLL-directed therapy during treatment.
Interim PET/CT was available in 18 patients: 78% of patients had a Deauville score of 1-3, 17% had a score of 4, and one patient had a score of 5. End-of-treatment PET/CT assessment was available in 15 patients; 14 (93%) achieved a Deauville score of 1-3, and one patient had a score of 5. Median follow-up time was 11 months (IQR 8-15). There were no deaths in this cohort. Among 15 evaluable patients with sufficient follow-up, the estimated 12-month PFS and overal survival from Kaplan-Meier were 100%. Only one patient experienced disease relapse at 15 months, received Nivolumab-ICE and High-dose therapy (HDT) with autologous stem cell transplantation, and is alive at the last follow-up.
The rareness of this diagnosis and the recency of N+AVD availability limited the cohort size. Lack of central pathology review and Hodgkin Reed-Sternberg cell microdissection for clonality assessment in routine clinical practice are additional limitations.
Conclusions:
In this multicenter retrospective cohort, first-line N+AVD demonstrated high complete metabolic response rates and encouraging early PFS rates in patients with CHL-RT, a population historically associated with suboptimal outcomes. Larger studies with longer follow-up data are needed.
DISCLOSURES
Raphael Steiner, MD: NCI - Research Funding; NCI - Research Funding